Reading NVAX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NVAX free→Reading NVAX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NVAX free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed, and risk is elevated. Peer multiples imply a price about 14% above where it trades (it looks cheap on this basis); the read is fair, but weakening. If NVAX cuts guidance on the next call, that's a meaningful negative. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 4 valuation methods, at three horizons. Current price $9.21. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $9.21 NVAX trades at 46× p/e — 2.7× the 17× p/e peer median. The market is re-rating it beyond its own range; our $10 fair value is low-confidence here. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 11% below a flat-multiple fair value, well above our forecast of about -60%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.04x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, Fed net liquidity, the US dollar, long-term interest rates.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.38 → $-0.38 (+0.0% / 30d). 0 raised, 4 cut, 7 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 56% of analysts rate Buy.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$229.
How much price usually moves either way.
On a bad day, this stock has moved -$612.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,594.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Company momentum fell by 25.0 points (from 60.0 to 35.0).
Confidence changed from 'medium' to 'high'.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
Loss of partnership with Sanofi impacts strategic positioning.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. First Quarter Financial Results On May 6, 2026, Novavax, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
NVAX Novavax, Inc. | Above typical Show detailsSector percentile: 84 of 100 | fair | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
15 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Novavax aims to achieve adjusted total revenue between $230 million and $270 million for 2026.
Stated in 2 of last 2 quarters. Revenue was $139.5M in 2026-Q1. The company has reiterated its revenue target for 2026, but current revenue levels suggest limited progress towards the lower end of the guidance range.
“Novavax reiterates its 2026 Revenue Framework and expects to achieve Adjusted Total Revenue of between $230 million and $270 million.”
“$155 - $175 million in Adjusted Licensing, Royalties and Other Revenue.”
Novavax targets full year Non-GAAP combined R&D and SG&A expenses of $325 million for 2026.
Stated in 2 of last 2 quarters. The company has consistently targeted $325M for R&D and SG&A expenses in 2026. However, without specific quarterly expense data, the trajectory towards this target remains unclear.
“Targeting full year Non-GAAP combined R&D and SG&A expenses of $325 million for full year 2026.”
Novavax entered a license agreement with Pfizer for its Matrix-M adjuvant technology.
Newly stated in 2026-Q1. The agreement with Pfizer represents a strategic growth initiative for Novavax. However, financial impacts from this agreement have not yet been reflected in the revenue figures for 2026-Q1.
“Novavax entered into a License and Option Agreement with Pfizer for the Matrix-M Technology.”
Loss of partnership with Sanofi impacts strategic positioning.
Results of Operations and Financial Condition. Third Quarter Financial Results On February 26, 2026, Novavax, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended December 31, 2025. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Entry into Material Definitive Agreements. License Agreement On January 15, 2026, (the “Effective Date”), Novavax, Inc. (the “Company”) entered into a License and Option Agreement (the “License and Option Agreement”) with Pfizer Inc. (“Pfizer”), collectively (the “Parties”). The License and Option Agreement provides a non-exclusive, worldwide, license, to the Company’s Matrix-M TM adjuvant technology (the “Matrix-M Technology”) for Pfizer to research, develop, and commercialize the Matrix-M T…
Results of Operations and Financial Condition On January 12, 2026, Novavax, Inc. (the “Company”) plans to provide an update for investors. The Company is in the process of finalizing its financial results for the year ended December 31, 2025, and the foregoing preliminary financial data is based on available information to date. This financial data for the year ended December 31, 2025 is preliminary and may change. This preliminary financial data has been prepared by, and is the responsibilit…
Results of Operations and Financial Condition. Third Quarter Financial Results On November 6, 2025, Novavax, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2025. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
“Non-GAAP Combined R&D and SG&A Expenses $310 - $340”